Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

Abstract: From PBMCs of patients infected with H1N1pdm, three human monoclonal antibodies have been obtained which are capable of binding to an epitope present at residues 40 to 58 in an HA2 region of a hemagglutinin protein derived from H1N1pdm. Further, these antibodies have been found to also have a neutralization activity against subtype H1 and subtype H5 of group 1 influenza A viruses. On the other hand, the three antibodies have also been found to exhibit neither a binding ability nor a neutralization activity against subtype H2 which belongs to the group 1, but in the HA2 region derived from H1N1pdm of which the amino acid at residue 45 is substituted with phenylalanine and the amino acid at residue 47 is substituted with glycine.

Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

Abstract: Antibodies (Abs) play roles in protection against influenza. Neutralizing Abs either inhibit the binding of hemagglutinin (HA) to cellular receptors or prevent the conformational change of HA induced by low pH. The former Ab binds to the regions near the sialic acid-binding pocket on the globular head formed by HA1 and generally shows narrow strain specificity. The latter Ab binds to the stem region formed mainly by HA2 and shows broad strain specificity. We isolated a broadly neutralizing Ab against H3N2 viruses. X-ray analysis of the HA/Ab complex indicated that the Ab binds to the valley formed by two neighboring HA monomers at the side of the globular head. The Ab shows neutralizing activity by preventing the conformational change of HA induced at low pH.

Abstract: The present invention provides a method and device of quantitatively or qualitatively examining and diagnosing chronic fatigue syndrome (CFS) by: irradiating a sample derived from an examinee or other animal with light having a wavelength in a range of 400 nm to 2500 nm or a wavelength in part of the range; detecting reflected light, transmitted light, or transmitted and reflected light to obtain an absorption spectral data; and analyzing absorbance at all measurement wavelengths or at specific wavelengths in the absorption spectral data by using an analytical model prepared beforehand.

Abstract: Antigenic peptides are provided that can be used to induce global neutralizing antibodies, or antibodies reactive against a wide range of influenza A virus strains. The antigenic peptide can correspond to SEQ ID NO: 34 (EKEVLVLWG), SEQ ID NO: 2 (KFDKLYIWG), SEQ ID NO: 71(QEDLLVLWG), SEQ ID NO: 51 (EGRINYYWTLLEP), SEQ ID NO: 3 (PSRISIYWTIVKP), and/or SEQ ID NO: 82 (SGRMEFFWTILKP).

Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

Abstract: An object of the present invention is to provide apparatuses for examining/diagnosing clinical disease of cancer, systemic lupus erythematosus (SLE), or antiphospholipid antibody syndrome. Blood, blood-derived component, urine, sweat, nail, skin, or hair is irradiated with light having a wavelength of 400 to 2,500 nm or a part of the range, of which the reflection light, the transmission light, or the transmission reflection light is then detected to give spectroscopic absorbance data, and afterward a previously prepared analysis model is used to analyze the absorbance over the whole wavelengths or at a specific wavelength for the measurement to allow the achievement of the object.

Abstract: The present invention is a method and an apparatus for examination/diagnosis of lifestyle related disease, wherein the test sample from a human or other animal subject is irradiated with light having a wavelength region of a region of 400 nm-2,500 nm or a part of the region, of which the reflection light, the transmission light, or the transmission reflection light is then detected to give spectroscopic data of absorbance, and afterward a previously prepared analysis model is used to execute an analysis of the absorbance at the whole or specific wavelength used for the measurement.

Abstract: The present invention provides a method and device of quantitatively or qualitatively examining and diagnosing chronic fatigue syndrome (CFS) by: irradiating a sample derived from an examinee or other animal with light having a wavelength in a range of 400 nm to 2500 nm or a wavelength in part of the range; detecting reflected light, transmitted light, or transmitted and reflected light to obtain an absorption spectral data; and analyzing absorbance at all measurement wavelengths or at specific wavelengths in the absorption spectral data by using an analytical model prepared beforehand.

Abstract: The present invention provides a method and device of quantitatively or qualitatively examining and judging the presence of virus infection, such as HIV, or the presence of prion infection by: irradiating a sample derived from an examinee or other animal with light having a wavelength in a range of 400 nm to 2500 nm or a wavelength in part of the range; detecting reflected light, transmitted light, or transmitted and reflected light to obtain an absorption spectral data; and analyzing the absorbance at all measurement wavelengths or at specific wavelengths in the absorption spectral data by using an analytical model prepared beforehand. The analytical model can be prepared by carrying out spectral measurement, with a perturbation being provided, and carrying out a multivariate analysis that brings out perturbation effects.

Abstract: A peptide having anti-HIV activity consists of an amino acid chain represented by Asn-Phe-Pro-Leu-Ile-Ile-Lys-Asn-Leu-Lys-Ile-Glu-Asp-Ser-Asp-Thr-Tyr-Ile-Cy s-Glu-Val-Glu-Asp-Gln-Lys-Glu. The Cys underlined in the above amino acid chain may be replaced by Phe, Ser, Cys.sup.Acm or Cys.sup.Bzl.

Abstract: A method for treatment of acquired immuno-deficiency syndrome (AIDS) which comprises administering a therapeutically effective amount of liposomes containing a toxin which specifically inhibits the protein synthesis in cells to a patient with AIDS.